Big, tax-exempt hospitals and clinics use the federal 340B program to generate massive profits at the expense of employers, taxpayers and patients. Comprehensive reform is needed to improve 340B program integrity, transparency and accountability.

Limited Oversight.

In 2024, only 0.33% of the 60,000 entities covered in the 340B program were audited by the federal government. That’s the same number of audits conducted in 2015 despite the program doubling in size over the last 4 years.

Skyrocketing Profits.

In 2025, hospitals, clinics and for-profit partners captured $142 billion in program profits. Community health center 340B sales increased by 31% in just one year, faster than the program overall.

Massive Markups.

The current system allows 340B hospitals and clinics to purchase medicines at steep discounts and mark them up, sometimes by 1000% or more.

A 340B Rebate Model is a Commonsense Step to Improve Transparency and Oversight

HRSA’s 340B Rebate Model Pilot Program represents a meaningful step toward bringing greater transparency to the program and addressing the lack of oversight. Rebates are a standard mechanism used across the health care system to confirm compliance with program requirements.

Report. Reimburse. Recoup.

The rebate model would follow a common claim-based process: covered entities would purchase 340B drugs upfront and receive a rebate after submitting basic claims data to make sure that key program requirements are being met.

If the money isn’t benefiting vulnerable communities, then where is it going? HRSA’s 340B Rebate Model Pilot is a test to bring more accountability to 340B and is an important step toward improving 340B program transparency.

The 340B program has ballooned in size, growing larger by 20% every year. The rebate model would apply to just about 5% of the program.

Just as you wouldn’t pay a restaurant bill without seeing the itemized receipt, a rebate model allows basic claims information to be verified before the 340B price is provided, helping prevent duplicate discounts and other program misuse.

FAQs: The 340B Rebate Model

A rebate-based approach strengthens 340B program integrity by requiring data to verify compliance with key program requirements before rebates are issued. Hospitals and clinics must provide the necessary information to demonstrate the claim is eligible. The added transparency of a rebate model would help prevent certain unauthorized duplicate discounts, which occur when, for example, a manufacturer provides a 340B discount and a Maximum Fair Price (MFP) rebate for the same drug. Such duplicate discounts are statutorily unauthorized.

Covered entities purchase eligible drugs at the wholesale acquisition cost (WAC) and submit required data to request 340B rebates. Manufacturers must pay or deny all rebates within 10 days of receiving a complete claim. The 340B pilot program only applies to 18 eligible drugs subject to the Medicare Drug Price Negotiation Program. The pilot program is designed to ensure that covered entities pay the same 340B ceiling price under the rebate model pilot as they would under the traditional, upfront-discount model, while helping prevent statutorily unauthorized duplicate 340B and MFP discounts.

The 340B rebate model pilot is scheduled to start on January 1, 2027.

Rebates are an established feature of the U.S. health care system. Many programs, including Medicaid and Medicare Part B and D, incorporate rebate systems.

The 340B rebate model pilot is designed to preserve hospitals’ access to the 340B price while improving transparency and program integrity. This commonsense approach can strengthen oversight and help ensure program requirements are followed. Rebates are expressly referenced in the 340B statute as a mechanism for providing reduced drug prices to hospitals and clinics and are routinely used in other health care programs.

Scroll to Top